Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

3(75.0%)

Phase 3

1(25.0%)

4Total

Phase 2(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT06486220Phase 3Not Yet Recruiting

PFLL Combined With PD-1 Antibody With or Without FMT for Oligometastatic NPC,a Phase III ,Open, Randomized Clinical Trial.

Role: lead

NCT02590133Phase 2Unknown

A Phase II Clinical Trial of Chemotherapy With or Without Endostar® Continuous Intravenous Infusion in Refractory NPC

Role: lead

NCT02735317Phase 2Unknown

Efficacy and Safety of FORRAD® for the Management of Radiation-induced Mucositis in Patients With Nasopharyngeal Carcinoma Receiving IMRT

Role: lead

NCT02729324Phase 2Unknown

Comparison of Efficacy and Safety Between Medical Radiation Protectants (FORRAD®) and Trolamine (Biafine) for the Management of Radiation Dermatitis in Patients With Nasopharyngeal Carcinoma Receiving IMRT

Role: lead

All 4 trials loaded